<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: HYPOTHESIS/INTRODUCTION: Our aim was to investigate whether a non-hypotensive dose of ramiprilat and <z:chebi fb="0" ids="6541">losartan</z:chebi> has myocardial protective effects during <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>/reperfusion in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Three groups of rats were given 10 mg/kg per day of <z:chebi fb="0" ids="6541">losartan</z:chebi> for one (L-1W), four (L-4W) or 10 (L-10W) weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Another three groups were given 50 µg/kg per day of ramiprilat for one (R-1W), four (R-4W) or 10 (R-10W) weeks </plain></SENT>
<SENT sid="3" pm="."><plain>The animals underwent 30 min of left anterior descending <z:mp ids='MP_0006134'>artery occlusion</z:mp> and subsequent reperfusion for 120 min </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size (IS) was reduced in R-1W (28.4 ± 6.3%, p &lt; 0.001), R-4W (27.8 ± 7.4, p &lt; 0.001), L-4W (31.8 ± 6%, p &lt; 0.05) and L-10W (25.3 ± 5.7, p &lt; 0.001) groups compared with a saline group (48.3 ± 7.8%) </plain></SENT>
<SENT sid="5" pm="."><plain>A significant reduction in the number of <z:mp ids='MP_0009732'>ventricular ectopic beats</z:mp> (VEBs) was noted in groups R-1W (209 ± 41, p &lt; 0.01), R-4W (176 ± 39, p &lt; 0.01), L-4W (215 ± 52, p &lt; 0.05) and L-10W (191 ± 61, p &lt; 0.01 vs. saline 329 ± 48) </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of irreversible <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) and mortality were decreased significantly only in L-10W group </plain></SENT>
<SENT sid="7" pm="."><plain>There were no significant decreases in episodes of VT, the incidence of irreversible <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and mortality in <z:hpo ids='HP_0000001'>all</z:hpo> of the groups treated with ramiprilat </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: These data indicate that <z:chebi fb="0" ids="6541">losartan</z:chebi> and ramiprilat protect the heart against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury independently of their hemodynamic effects but in a time-dependent manner </plain></SENT>
</text></document>